FLT3 and acute myeloid leukemia: Acute myeloid leukemia (AML) patients with the FMS‐related receptor tyrosine kinase 3 internal tandem duplication (FLT3/ITD) mutation have a poorer prognosis, and treatment with FLT3 tyrosine kinase inhibitors (TKIs) has been hindered by resistance mechanisms.